A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Conclusions CP-870,893 with cisplatin and pemetrexed is safe and tolerable at 0.15 mg/kg, although most patients experience CRS. While objective response rates are similar to chemotherapy alone, three patients achieved long-term survival. Australia New Zealand Clinical Trials Registry number ACTRN12609000294257. (Source: Annals of Oncology)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=153676160&cid=c_409_6_f&fid=31077&url=http%3A%2F%2Fannonc.oxfordjournals.org%2Fcgi%2Fcontent%2Fshort%2F26%2F12%2F2483%3Frss%3D1